Nitin Jain: The U.S. FDA approves lisocabtagene maraleucel for adults with relapsed or refractory CLL or SLL

Nitin Jain, The Director of the Leukemia CAR-T Program at the MD Anderson Cancer Center, shared a post by Jordan Gauthier, Associate Professor at Fred Hutch Cancer Centre and University of Washington on X/Twitter, adding: 

“Wonderful news for patients with CLL! Adds another treatment option for patients who have received prior BTKi and BCL2il.”

Quoting Jordan Gauthier’s post:

“The U.S. FDA approves Bristol Myers Squibb lisocabtagene maraleucel for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Kudos to all investigators and sites involved!”

Source: Nitin Jain/X and Jordan Gauthier/X